DOCSLIB.ORG

State of Medicon Valley 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
State of Medicon Valley 2016 STATE OF MEDICON VALLEY 2016 An Analysis of Life Science in Greater Copenhagen PREFACE Life science in Denmark and Sweden has developed in different directions over the past decade. Danish life science exports doubled in seven years, and last year they were nearly 50% greater than Swedish. The number of employees has risen, and thanks to a well-developed system with industrial foundations, the large companies’ headquarters and major shareholders are still in Denmark. At the same time in Sweden, more large companies are now foreign-owned, the largest headquarters have left the country and more important operations have either shrunken in scale or closed down, and the number of employees in the sector has diminished. But there are signs of a change for the better in the university city Lund as well as in Södertälje, Stockholm and Uppsala, visible with for example new biotechnology companies, new research facilities and new investments in the R&D of biological medicines. It is part of a new phase in the life science sector’s global transition, and it is also perceptible in Denmark as the simultaneous reports of cutbacks and the hiring of new competence. Medicon Valley Alliance is also in a transitional phase, with a new strategy that focuses more on our role as a networking organisation for the life science cluster on both sides of the Öresund. Part of our upgraded ambition is to increase knowledge about the compa- nies and research in Medicon Valley. This is the first edition of our new annual analytic report State of Medicon Valley, which offers a unique presentation of life science develop- ments in our region, on a macro- as well as a micro-scale. Measuring developments in a sector like life science is a challenge; there are no clearly defined statistical definitions for the sector, and there are also overlaps, which further increases the complexity. That makes this analysis more important than ever. The analysis reveals that Greater Copenhagen has developed into the leading Nordic regi- on for life science in the past ten years. The majority of the Danish life science companies are located in the Region, and Medicon Valley overshadows the other Nordic countries when it comes to the number of international patent applications for life science. On the STATE OF MEDICON VALLEY 2016 other side of the Strait in the Skåne region, a new beacon is being erected with the new materials research facilities ESS and MAX IV, which will become an important resource An Analysis of Life Science in Greater Copenhagen for the Region’s life science companies. There is also fertile ground for new companies in the Region’s many established and emerging science parks such as COBIS, Scion DTU, Commissioned and published by: Medicon Valley Alliance. Symbion, Medeon, Medicon Village and Ideon. This analysis has been prepared by Øresundsinstituttet and was written by Britt Andresen, Johan Wessman, Jenny Andersson, State of Medicon Valley 2016 is the first of a long-term analysis collaboration between Anna Palmehag and Thea Wiborg. Layout: Jenny Andersson. Medicon Valley Alliance and Øresundsinstituttet. The analysis will be released every year, Cover photo: Genmab and each year will bring an in-depth investigation of a new topic. Special reports are plan- ned for release throughout the year. The analysis is part of an open process, where you – the sector’s players – are welcome to contribute with your points of view and reflections. November 2016 Updated version. Copenhagen and Malmö 7 November 2016 Petter Hartman CEO Medicon Valley Alliance PHOTO: BAVARIAN NORDIC BAVARIAN PHOTO: TABLE OF CONTENTS 1. SUMMARY ..................................................................................................................... 6 2. LIFE SCIENCE IN SWEDEN AND DENMARK ............................................................... 10 3. LIFE SCIENCE IN MEDICON VALLEY ........................................................................... 24 4. THE BEACONS OF MEDICON VALLEY ......................................................................... 32 5. NEW COMPANIES IN MEDICON VALLEY ..................................................................... 46 6. BENCHMARK OF RESEARCH QUALITY ......................................................................... 52 7. ATTRACTING AND KEEPING TALENT ............................................................................ 64 8. ANALYSIS .................................................................................................................... 72 9. APPENDIX ................................................................................................................... 88 - STATISTICS AND METHODOLOGY ................................................................................... 89 - INTERVIEW LIST............................................................................................................... 92 - LARGER MEETINGS AND CONFERENCES ..................................................................... 93 - REPORTS AND FACTS ..................................................................................................... 94 - ORGANISATIONS .............................................................................................................. 96 - REFERENCE LIST ............................................................................................................ 98 PHOTO: BAVARIAN NORDIC BAVARIAN PHOTO: SUMMARY 35 700 NEWS ØRESUND PHOTO: was the number of employees at life science companies in Medicon Valley in LUNDBECK PHOTO: 2014. That is equal to 53% of the total number of employees in the life science industry in Denmark and Sweden. The number of employees has increased by 4% since 2008. Novo Nordisk was Medicon Valley’s tallest beacon with its almost 40 000 employees in December of 2015. In the same year, plans 124 500 employees in were made for several billion-crown invest- the health care sector ments in new facilities. Recently however, the company announced that it was no The health care sector in the Greater longer hiring, later cutting 1 000 jobs, 500 of Copenhagen Region employs 124 500 which were in Denmark. people, some 85 000 of whom are in Eastern Denmark. That means that TRANSITION TIME close to 160 000 people in the region work within life science and health FOR MEDICON VALLEY care. In addition to those are resear- chers at the region’s universities. 50% In the past 10-15 years, Medicon Valley has grown to be the Danish life science exports are nearly 50% strongest Nordic life science cluster. There have been succes- greater than Swedish. Danish pharmaceu- ses for the four big pharmaceutical companies Novo Nordisk, tical exports and health technology will H. Lundbeck, Ferring and LEO Pharma, and there is a new surpass agricultural exports in a few years. wave of biotech companies that emerged around the turn of the millennium. During the financial crisis, pharma companies continued to grow with Novo Nordisk at the forefront, and the – The conditions, with high tax rates and over- biotech wave temporarily lost its power. PHOTO: NEWS ØRESUND PHOTO: head costs are miserable. No-one would start Medicon Valley is now in a period of transition. Novo Nordisk a pharmaceutical company in Denmark today, is confronting more price pressure in the USA with staff cut- says Kåre Schultz, CEO of Lundbeck and chair- backs, while last year the company also decided to make a number of billion-crown investments. H. Lundbeck is rising from man of the Danish government’s life science a dip with a renewed patent portfolio. LEO Pharma is letting off growth team. See interview on page 78. 400 and hiring 200 to adjust competence to the new biological medicines, and the company is investing in an innovation lab in the USA where the interface between pharmaceuticals and 22 billion Swedish crowns are apps for medicine use are being developed. On the shore of the Öresund, next to Copenhagen’s international airport in Kastrup, being invested in ESS and MAX IV 2x Ferring Pharmaceuticals is setting its roots around the Öresund Medicon Valley is on top in with a billion-crown investment in the new research facility faci- Medicon Valley is getting a new beacon – the two facilities Denmark and Sweden, submit- lity Soundport. The region’s science parks continue to grow and for materials research MAX IV and ESS in Lund, with ESS’ ting the greatest number the new biotech companies have also picked up growth again. data management centre in Copenhagen. The facilities of patent applications to EPO And the regions new beacon is rising in Lund: the materials will improve the balance within Medicon Valley; Zealand and with more than two times as research facilities MAX IV and European Spallation Source, ESS. dominates industrially, but Lund is growing into a centre many patent applications than for the natural sciences. Stockholm-Uppsala region. STATE OF MEDICON VALLEY • November 2016 7 SUMMARY SUMMARY Things are going well for Danish life science. Not so making cutbacks. Cost-consciousness has definitely research in the natural sciences as main purpose. with ESS’ data management centre in Copenhagen. for Swedish life science. That has been the general reached the life science sector. Zealand is significantly larger than Skåne if the Interestingly, there are Danish investments in both picture of life science in the two countries for the past One area that is often unduly neglected is municipalities around Copenhagen are included. research facilities that are clearly linked to the pos-
Load more

Recommended publications
  • Life After Shrinkage
    LIFE AFTER SHRINKAGE CASE STUDIES: LOLLAND AND BORNHOLM José Antonio Dominguez Alcaide MSc. Land Management 4th Semester February – June 2016 Study program and semester: MSc. Land Management – 4th semester Aalborg University Copenhagen Project title: Life after shrinkage – Case studies: Lolland and Bornholm A.C. Meyers Vænge 15 2450 Copenhagen SV Project period: February – June 2016 Secretary: Trine Kort Lauridsen Tel: 9940 3044 Author: E-mail: [email protected] Abstract: Shrinkage phenomenon, its dynamics and strategies to José Antonio Dominguez Alcaide counter the decline performed by diverse stakeholders, Study nº: 20142192 are investigated in order to define the dimensions and the scope carried out in the places where this negative transformation is undergoing. The complexity of this process and the different types of decline entail a study in Supervisor: Daniel Galland different levels from the European to national (Denmark) and finally to a local level. Thus, two Danish municipalities Pages 122 (Lolland and Bornholm) are chosen as representatives to Appendix 6 contextualize this inquiry and consequently, achieve more accurate data to understand the causes and consequences of the decline as well as their local strategies to survive to this changes. 2 Preface This Master thesis called “Life after shrinkage - Case studies: Lolland and Bornholm” is conducted in the 4th semester of the study program Land Management at the department of Architecture, Design and Planning (Aalborg University) in Copenhagen in the period from February to June 2016. The style of references used in this thesis will be stated according to the Chicago Reference System. The references are represented through the last name of the author and the year of publication and if there are more than one author, the quote will have et al.
    [Show full text]
  • State of Medicon Valley 2018
    A COMPARISON OF SCIENTIFIC PUBLICATIONS IN 10 EUROPEAN LIFE SCIENCE CLUSTERS STOCKHOLM-UPPSALA SCOTLAND MEDICON VALLEY NETHERLANDS LONDON-CAMBRIDGE-OXFORD FLANDERS ÎLE DE FRANCE BIOVALLEY MUNICH ZURICH STATE OF MEDICON VALLEY 2018 An Analysis of Life Science in Greater Copenhagen PREFACE Medicon Valley is in a period of transition. The life science sector has been the region’s growth motor, even through the darkest years of the economic crisis. But now is no time to rest on laurels. The sector is facing new research breakthroughs in everything from personalised medicine to biopharmaceuticals and gene therapy. The dividing lines to other sectors are being dissolved with new digital solutions and arti- ficial intelligence that in part facilitate diagnostics and in part give patients increased control over their care. One of the most important foundations for the creation of a competitive life science cluster is the access to – and the emergence of – internationally leading university environments and research institutions. For this reason, we have commissioned a unique comparison of Europe’s ten most influential life science clusters, based on scientific publication volume in the life sciences, from the Dutch research institute CWTS at Leiden University. We’re happy to report that the percentual increase in scientific publications in the life sciences is greater in Medicon Valley than in any other cluster in Europe’s other Top Ten. Calculated according to the number of publications, the region’s placement is firmly in the middle of the list, at the top of which is the life science cluster in Lon- STATE OF MEDICON VALLEY 2018 don-Cambridge-Oxford.
    [Show full text]
  • Letter Without Tagline
    CH D Press release DONGBAO TO ACQUIRE FERRING’S MALMÖ MANUFACTURING OPERATION Saint Prex, Switzerland and Shanghai, China, Friday 17 November, 2006 – Ferring Pharmaceuticals and Shanghai Dongbao Biopharmaceutical Company announced today the signing of an agreement by which Dongbao Biopharmaceutical will purchase Ferring’s manufacturing operation at Malmö in Sweden. Earlier this year, Ferring informed staff of its plan to cease manufacturing at Malmö by the end of March 2008. However, the acquisition by Dongbao Biopharmaceutical has secured the jobs of around 50 members of staff. The agreement will become effective on 1 January, 2007. “From the very beginning, our aim has been to find a solution which would maintain the Malmö production site,” commented Ferring Pharmaceuticals Chief Operating Officer, Michel Pettigrew. “This agreement is a boost for the local community and has secured the long-term future of the factory for around 50 employees, whose experience will be invaluable to Dongbao Biopharmaceutical.” “We see great potential for the manufacturing centre at Malmö,” added Dr George Li, President of Dongbao Biopharmaceutical. “The site is technically very developed and the current team, who will be an important part of our future business development, offer a lot of knowledge and competencies.” Ends Ferring International Center S.A., Chemin de la Vergognausaz 50, 1162 Saint‐Prex, Switzerland Tel: +41 58 301 00 00, Fax: +41 58 301 00 10, www.ferring.com CH About Ferring: Ferring is a Swiss-based research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology.
    [Show full text]
  • Triptorelin Pamoate (Subcutaneous Injection) for Prostate Cancer NIHRIO (HSRIC) ID: 20540 NICE ID: 9841
    NIHR Innovation Observatory Evidence Briefing: May 2018 Triptorelin pamoate (subcutaneous injection) for prostate cancer NIHRIO (HSRIC) ID: 20540 NICE ID: 9841 LAY SUMMARY Prostate cancer is cancer of the prostate gland (a small organ in a man’s pelvis) and is the second most common cancer in the UK. There are three stages: localised, locally‐advanced and advanced (or metastatic) prostate cancer. The symptoms of prostate cancer may vary depending on the stage of cancer but can include pain, tiredness, problems emptying the bladder and the bowels. About half of men diagnosed with locally‐advanced prostate cancer will see their cancer spread to other body organs (i.e. becoming metastatic). Triptorelin is being developed as an injection under the skin (subcutaneous) for the treatment of locally advanced or metastatic prostate cancer. It is already marketed for this condition but is given by injection deep into the muscles (intramuscular). Triptorelin is an artificial analogue of natural gonadotropin‐releasing hormone that acts to slowly reduce the level of testosterone in the body. The first administration of triptorelin stimulates an increase in testosterone levels but prolonged administration leads to a fall in plasma testosterone or oestradiol to castrate levels which is maintained for as long as the product is administered. Triptorelin as a subcutaneous injection formulation has the potential advantage of improved safety and local tolerability when compared to intramuscular injection formulation. This briefing reflects the evidence available at the time of writing. A version of the briefing was sent to the company for a factual accuracy check. The company was available to provide comment.
    [Show full text]
  • Villum Fonden
    VILLUM FONDEN Technical and Scientific Research Project title Organisation Department Applicant Amount Integrated Molecular Plasmon Upconverter for Lowcost, Scalable, and Efficient Organic Photovoltaics (IMPULSE–OPV) University of Southern Denmark The Mads Clausen Institute Jonas Sandby Lissau kr. 1.751.450 Quantum Plasmonics: The quantum realm of metal nanostructures and enhanced lightmatter interactions University of Southern Denmark The Mads Clausen Institute N. Asger Mortensen kr. 39.898.404 Endowment for Niels Bohr International Academy University of Copenhagen Niels Bohr International Academy Poul Henrik Damgaard kr. 20.000.000 Unraveling the complex and prebiotic chemistry of starforming regions University of Copenhagen Niels Bohr Institute Lars E. Kristensen kr. 9.368.760 STING: Studying Transients In the Nuclei of Galaxies University of Copenhagen Niels Bohr Institute Georgios Leloudas kr. 9.906.646 Deciphering Cosmic Neutrinos with MultiMessenger Astronomy University of Copenhagen Niels Bohr Institute Markus Ahlers kr. 7.350.000 Superradiant atomic clock with continuous interrogation University of Copenhagen Niels Bohr Institute Jan W. Thomsen kr. 1.684.029 Physics of the unexpected: Understanding tipping points in natural systems University of Copenhagen Niels Bohr Institute Peter Ditlevsen kr. 1.558.019 Persistent homology as a new tool to understand structural phase transitions University of Copenhagen Niels Bohr Institute Kell Mortensen kr. 1.947.923 Explosive origin of cosmic elements University of Copenhagen Niels Bohr Institute Jens Hjorth kr. 39.999.798 IceFlow University of Copenhagen Niels Bohr Institute Dorthe DahlJensen kr. 39.336.610 Pushing exploration of Human Evolution “Backward”, by Palaeoproteomics University of Copenhagen Natural History Museum of Denmark Enrico Cappellini kr.
    [Show full text]
  • Science Parks in Medicon Valley 2018
    SCIENCE PARKS IN MEDICON VALLEY 2018 An Analysis of Life Science- oriented Science Parks in Greater Copenhagen PREFACE University research in the Danish-Swedish Greater Copenhagen region needs to generate more new companies, and large-scale companies need a hand breathing new life into their innovation endeavours. Those are two of the goals behind recent years’ investments in the region’s science parks, incubators and accelerators. In many cases, the new investments target the life sciences and the region’s cluster, Medicon Valley. The new flagship is called the BioInnovation Institute, BII, and it started up earlier this year at COBIS in central Copen- hagen. BII has a budget of 392 million DKK, dispersed over three years, and is funded by the Novo Nordisk Foundation. The initiative has its origins in a sombre verdict: too few new companies have emerged from the life science research being done at the universities. Continued investments in the region’s science parks are crucial if Medicon Valley is to hold its own against life science clusters all over the globe. The most successful clusters are the ones that attract the best researchers and the most important investors. Medicon Valley Alliance’s new analysis focuses on the powerful developments in the regi- on’s science parks. This report profiles five science parks in Medicon Valley that are either fully or significantly focused on the life sciences: COBIS, DTU Science Park, Ideon, Medeon and Medicon Village. The overview also includes the start-up ecosystem Symbion in Copen- hagen and the food- and health-oriented science park Krinova in Kristianstad.
    [Show full text]
  • REKOVELLE®, the First Recombinant Follicle Stimulating Hormone Derived
    REKOVELLE®, the first recombinant follicle stimulating hormone derived from a human cell line, is now available for Canadian women undergoing IVF and other assisted reproductive technologies REKOVELLE® helps women achieve a more predictable and targeted ovarian response Toronto, Ontario – 29 October 2018 – Ferring Pharmaceuticals announced that REKOVELLE® (follitropin delta injection), the first recombinant FSH for controlled ovarian stimulation derived from a human cell line, is now available in Canada for women undergoing assisted reproductive technologies such as in vitro fertilization (IVF).1 Ovarian response to stimulation varies considerably from woman to woman,2 and unexpected extreme responses have implications on efficacy and safety.3,4 REKOVELLE® is the first gonadotropin to use an evidence-based, personalized dosing algorithm based on a woman’s anti-Müllerian hormone (AMH) level and body weight to achieve a predictable ovarian response.1 “One in six Canadian couples experience infertility and many couples feel anxious about the unknowns of reproductive medicine when they go through IVF for the first time,” says Dr. Al Yuzpe, Reproductive Endocrinologist, Co-Founder and Co-Director of Olive Fertility Centre in Vancouver. “REKOVELLE® provides a more predictable and personalized option considering each woman’s AMH and body weight. We finally have an FSH preparation that is dosed based on scientific evidence, removing the subjective decision of choosing the appropriate dosage of FSH for each woman.” REKOVELLE® was approved by Health Canada on March 22, 2018, and is the first gonadotropin to be granted Innovative Drug status by Health Canada.5 “We are proud to lead the way towards a more innovative and personalized care approach for women undergoing IVF,” said Lee Ferreira, General Manager, Ferring Pharmaceuticals.
    [Show full text]
  • LIFE11 ENV/DK/889 Progress Report 21/09/2014 Stream of Usseroed
    LIFE Project Number LIFE11 ENV/DK/889 Progress Report Covering the project activities from 01/11/2012 to 01/07/2014 Reporting Date 21/09/2014 LIFE+ PROJECT NAME or Acronym Stream of Usseroed – Joint Flood Solution Data Project Project location North Zealand Region, Denmark Project start date: 03-09-2012 Project end date: 29-02-2016 Total budget 2,530,689 € EC contribution: 931,728€ (%) of eligible costs 49.98 Data Beneficiary Name Beneficiary Fredensborg Municipality Contact person Mr. Klaus Pallesen Postal address Egevangen 3B, 2980 Kokkedal, Denmark Telephone +45 7256 5000 direct n°+45 7256 2398 Fax: E-mail [email protected] Project Website Usseroed_aa.dk LIFE11 ENV/DK/899 Progress Report Stream of Usseroed Aug 2014 List of contents 1. Abbreviations applied in the progress report: ....................................................... 3 2. Executive summary .................................................................................................. 4 2.1 General progress ........................................................................................ 5 2.2 Problems encountered ................................................................................ 5 2.3 Viability of projecet objectives and work plan .......................................... 6 3. Administrative part .................................................................................................. 6 3.1 Project organization ................................................................................... 6 3.2 Project management activities
    [Show full text]
  • Download White Paper
    8 important considerations when relocating your life science business Surround your company with a knowledge-based environment Join a successful life science cluster Easy access PART OF 1 Provide your business with the best conditions for growth by becoming part of one of the world’s leading life science clusters Did you know that Denmark is a leader in the field of life science, and that the This white paper Medicon Valley business cluster in Greater Copenhagen is the international This white paper will provide you epicentre of Scandinavian life sciences? with information about the life science industry in the Municipality Here we have a vibrant ecosystem of Ballerup – a part of Greater and a deep talent pool underpinned by Copenhagen. You will find world-class life science universities and 8 important factors when research infrastructure. considering whether to relocate to Ballerup, and why our life science cluster is the ideal location for you. Success creates more success – the story of our region Our region is successful because the life science businesses here are successful. The life science industry in Greater Copenhagen grows stronger every day, because it both benefits from, and contributes to a unique ecosystem comprising businesses, universities and the public sector. The success of others gives you the best possible conditions for creating your own growth and thoroughly succeeding as a life science region. And your business is most welcome. You too can be a part of our success – and growth. 2 Surround your company with knowledge-based
    [Show full text]
  • Ferring Pharmaceuticals and Kyowa Kirin Announce Termination the License Agreement and the Supply and Co-Promotion Agreement Of
    Ferring Pharmaceuticals and Kyowa Kirin Announce Termination the License Agreement and the Supply and Co-Promotion Agreement of Pharmaceutical Products of Desmopressin Tokyo, February 25, 2020 — Ferring Pharmaceuticals Co., Ltd. (Tokyo Japan; President and CEO: Mark Noggle, “Ferring”) and Kyowa Kirin Co., Ltd., (Tokyo Japan; President and CEO:Masashi Miyamoto, “Kyowa Kirin”) today announced that Kyowa Kirin transfers all marketing authorizations for the products of desmopressin*1 (generic name: Desmopressin Acetate Hydrate) to Ferring effective on and from April 27, 2020, and they terminate the license agreement and the supply and co-promotion agreement about these products of desmopressin and MINIRINMELT®OD Tablet (Desmopressin Acetate Hydrate Orally Disintegrating Tablet) on the same day. The seven products subjected to the termination are listed below. Ferring and Kyowa Kirin have co-promoted for the seven products and Kyowa Kirin has distributed them. Kyowa Kirin terminates to distribute the products on April 26,2020 upon termination of the license agreement. Product Listing Generic name Product name Main indication Supplier Distributor Desmopressin MINIRINMELT®OD Central diabetes Ferring Kyowa Kirin Acetate Tablet Insipidus*2 Pharmaceuticals Co., Ltd. Hydrate (60 ㎍/120 ㎍/240 ㎍) Co., Ltd. DESMOPRESSIN Central diabetes Kyowa Kirin Co., Intranasal 0.01% Insipidus Ltd. Kyowa DESMOPRESSIN・ Spray 2.5 Kyowa DESMOPRESSIN・ Nocturnal enuresis / *3 Spray 10 Kyowa bedwetting DESMOPRESSIN Hemophillia A Injection 4 Kyowa von Willebrand’s disease *1 About Desmopressin Desmopressin is a synthetic analog of antidiuretic hormone (vasopressin), an artificial peptide consisting of 8 amino acids. The drug has a strong antidiuretic action that concentrates the urine and decreases urine output. *2 About central diabetes insipidus Central diabetes insipidus is a disease caused by reduced or absent synthesis or secretion of antidiuretic hormone known as arginine vasopressin (AVP) that causes symptoms such as excessive urination as well as extreme thirst and increased fluid intake.
    [Show full text]
  • OECD Reviews of Regional Innovation OECD Reviews of Regional Central and Southern Denmark
    OECD Reviews of Regional Innovation Regional of Reviews OECD Central and Southern Denmark Contents OECD Reviews of Regional Innovation Assessment and recommendations Introduction Central Chapter 1. Innovation and the economies of Central and Southern Denmark Chapter 2. Danish governance and policy context for regional strategies and Southern Denmark I Chapter 3. Regional strategies for innovation-driven growth nnovation C e nt r al an al d So uth er n D n Please cite this publication as: e OECD (2012), OECD Reviews of Regional Innovation: Central and Southern Denmark 2012, nma OECD Publishing. http://dx.doi.org/10.1787/9789264178748-en r k This work is published on the OECD iLibrary, which gathers all OECD books, periodicals and statistical databases. Visit www.oecd-ilibrary.org, and do not hesitate to contact us for more information. isbn 978-92-64-17873-1 04 2012 09 1 P -:HSTCQE=V\]\XV: 042012091.indd 1 08-Aug-2012 2:19:29 PM OECD Reviews of Regional Innovation: Central and Southern Denmark 2012 This work is published on the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of the Organisation or of the governments of its member countries. This document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. Please cite this publication as: OECD (2012), OECD Reviews of Regional Innovation: Central and Southern Denmark 2012, OECD Publishing.
    [Show full text]
  • The Danish Pharma and Biotech Industry
    MINISTRY OF FOREIGN AFFAIRS OF DENMARK Invest in Denmark 2021 THE DANISH PHARMA AND BIOTECH INDUSTRY www.investindk.com Denmark: best country for business Gateway to the Nordics Four international airports serve tourism, business and cargo. Copenhagen Airport has direct international routes to more than 184 destinations as per January, 2020, making it by far the largest airport and logistics hub in the Nordics. #1 in europe for ease USD 60,195 of doing business GDP per capita The World Bank (2008-2020) OECD (2020) #1 in the world #3 on the OECD Better Life Index future readiness to exploit 22% (2020) digital transformation corporate IMD (2020) tax Strong infrastructure Denmark has a strong infrastructure includ- ing six international airports, sea ports, bridges and an integrated railway system. Together, they enable easy distribution of goods and services to the Nordic markets. Denmark aims to be powered entirely by renewable sources by 2050 #1 in the world attracting and retaining talents Language IMD (2020) Lowest redundancy 9 out of 10 people costs in the world speak English and Shared #1, IMD (2020) 5 out of 10 speak German. #1 in the world on social responsibility One of the most flexible labour markets in the world of business leaders IMD (2020) IMD (2020) 2 | The Danish Pharma and BioTech Industry AMONG THE BEST AND MOST INNOVATIVE IN THE WORLD As the European leader in drug development, Denmark offers attractive busi- ness solutions for foreign biotech companies. This includes R&D collaborations with Danish universities and research organisations, establishing European headquarters or entering into a strategic partnership regarding fast develop- ment or approval of your product for the European market.
    [Show full text]